Purpose: Aim was to analyze demographic and tumor characteristics, treatment, and survival of patients with lung cancer younger than 40 years of age (U40) compared to older subgroups (41-70 and >70 years).
Methods: We analyzed data of young patients diagnosed and treated in 2011-2019 in five pneumo-oncology centers in Czechia. Standard descriptive statistics, chi-squared test, Fisher exact test, and Kaplan-Meier survival analysis were used. p-Values <0.05 were considered significant. These data were compared with two control subgroups (cohort 1: 41-70 years, cohort 2: >70 years).
Results: We identified 66 patients U40, 61 with non-small cell lung cancer (NSCLC)-50.8% men, mean age 34.6 years, 54.1% nonsmokers, daily good performance status, and 82% in stage IV. Adenocarcinomas dominated, endothelial growth factor receptor (EGFR) positivity was less common than in older groups contrary to anaplastic lymphoma kinase (ALK) mutations. Median progression-free survival was 3.7 months (vs. 4.9 and 6.2 months; p = 0.006) and overall survival reached 11.7 months (vs. 22.3 and 27.3 months; p < 0.001). Young patients in stage IV and never-smokers had shorter survival than older patients.
Conclusion: Patients with NSCLC U40 had significantly worse prognosis than older patients.
BRATOVÁ, Monika, Kristián BRAT, Karolina HURDALKOVA, Magda BARINOVA, Marie DROSSLEROVA, Juraj KULTAN, Matyas WANKE, Leona KOUBKOVA, Jana KREJCI and Martin SVATON. Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity? JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY. NEW ROCHELLE: MARY ANN LIEBERT, INC, 2022, vol. 11, No 5, p. 451-458. ISSN 2156-5333. Available from: https://dx.doi.org/10.1089/jayao.2021.0069.
@article{1834739, author = {Bratová, Monika and Brat, Kristián and Hurdalkova, Karolina and Barinova, Magda and Drosslerova, Marie and Kultan, Juraj and Wanke, Matyas and Koubkova, Leona and Krejci, Jana and Svaton, Martin}, article_location = {NEW ROCHELLE}, article_number = {5}, doi = {http://dx.doi.org/10.1089/jayao.2021.0069}, keywords = {non-small cell lung cancer; young patients; younger than the age of 40 years; overall survival; prognosis; mutations}, language = {eng}, issn = {2156-5333}, journal = {JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY}, title = {Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?}, url = {https://www.liebertpub.com/doi/10.1089/jayao.2021.0069}, volume = {11}, year = {2022} }
TY - JOUR ID - 1834739 AU - Bratová, Monika - Brat, Kristián - Hurdalkova, Karolina - Barinova, Magda - Drosslerova, Marie - Kultan, Juraj - Wanke, Matyas - Koubkova, Leona - Krejci, Jana - Svaton, Martin PY - 2022 TI - Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity? JF - JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY VL - 11 IS - 5 SP - 451-458 EP - 451-458 PB - MARY ANN LIEBERT, INC SN - 21565333 KW - non-small cell lung cancer KW - young patients KW - younger than the age of 40 years KW - overall survival KW - prognosis KW - mutations UR - https://www.liebertpub.com/doi/10.1089/jayao.2021.0069 N2 - Purpose: Aim was to analyze demographic and tumor characteristics, treatment, and survival of patients with lung cancer younger than 40 years of age (U40) compared to older subgroups (41-70 and >70 years).
Methods: We analyzed data of young patients diagnosed and treated in 2011-2019 in five pneumo-oncology centers in Czechia. Standard descriptive statistics, chi-squared test, Fisher exact test, and Kaplan-Meier survival analysis were used. p-Values <0.05 were considered significant. These data were compared with two control subgroups (cohort 1: 41-70 years, cohort 2: >70 years).
Results: We identified 66 patients U40, 61 with non-small cell lung cancer (NSCLC)-50.8% men, mean age 34.6 years, 54.1% nonsmokers, daily good performance status, and 82% in stage IV. Adenocarcinomas dominated, endothelial growth factor receptor (EGFR) positivity was less common than in older groups contrary to anaplastic lymphoma kinase (ALK) mutations. Median progression-free survival was 3.7 months (vs. 4.9 and 6.2 months; p = 0.006) and overall survival reached 11.7 months (vs. 22.3 and 27.3 months; p < 0.001). Young patients in stage IV and never-smokers had shorter survival than older patients.
Conclusion: Patients with NSCLC U40 had significantly worse prognosis than older patients.
ER -
BRATOVÁ, Monika, Kristián BRAT, Karolina HURDALKOVA, Magda BARINOVA, Marie DROSSLEROVA, Juraj KULTAN, Matyas WANKE, Leona KOUBKOVA, Jana KREJCI and Martin SVATON. Lung Cancer Versus ''Young Cancer'': Is Non-Small Cell Lung Cancer in Young Patients a Different Entity? \textit{JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY}. NEW ROCHELLE: MARY ANN LIEBERT, INC, 2022, vol.~11, No~5, p.~451-458. ISSN~2156-5333. Available from: https://dx.doi.org/10.1089/jayao.2021.0069.